Objective:In this study, the effects of bortezomib and vincristine combined with dexamethasone and thalidomide on immune function, inflammatory response, renal function, myeloma cells and plasma cells in patients with...Objective:In this study, the effects of bortezomib and vincristine combined with dexamethasone and thalidomide on immune function, inflammatory response, renal function, myeloma cells and plasma cells in patients with multiple myeloma were compared.Methods:68 patients with multiple myeloma treated in our hospital from May 2009 to Nov. 2018 were selected and divided into control group and observation group according to the drugs used in chemotherapy. The control group was treated with vincristine combined with dexamethasone and thalidomide, while the observation group was treated with bortezomib combined with dexamethasone and thalidomide. Immunocytes, inflammatory cytokines, serum creatinine, blood urea nitrogen, myeloma cells and plasma cells were detected before and after treatment in the two groups.Results: There was no significant difference in each index between the two groups before treatment (P>0.05). After three courses of chemotherapy, CD3+, CD4+, CD4+/CD8+ and Treg in the observation group were significantly better than those in the control group, and the difference between the two groups was statistically significant (P<0.05). The levels of inflammatory cytokines CRP, TNF-α, myeloma cells and M protein were significantly decreased in the observation group (P<0.05). Renal function indexes in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in clinical efficacy and adverse reactions between the two groups (P<0.05).Conclusion: Bortezomib combined with dexamethasone and thalidomide can effectively reduce the inflammatory response, M protein and myeloma cells in patients with MM, significantly improve the immune function and renal function in patients, which has certain clinical application value.展开更多
文摘Objective:In this study, the effects of bortezomib and vincristine combined with dexamethasone and thalidomide on immune function, inflammatory response, renal function, myeloma cells and plasma cells in patients with multiple myeloma were compared.Methods:68 patients with multiple myeloma treated in our hospital from May 2009 to Nov. 2018 were selected and divided into control group and observation group according to the drugs used in chemotherapy. The control group was treated with vincristine combined with dexamethasone and thalidomide, while the observation group was treated with bortezomib combined with dexamethasone and thalidomide. Immunocytes, inflammatory cytokines, serum creatinine, blood urea nitrogen, myeloma cells and plasma cells were detected before and after treatment in the two groups.Results: There was no significant difference in each index between the two groups before treatment (P>0.05). After three courses of chemotherapy, CD3+, CD4+, CD4+/CD8+ and Treg in the observation group were significantly better than those in the control group, and the difference between the two groups was statistically significant (P<0.05). The levels of inflammatory cytokines CRP, TNF-α, myeloma cells and M protein were significantly decreased in the observation group (P<0.05). Renal function indexes in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in clinical efficacy and adverse reactions between the two groups (P<0.05).Conclusion: Bortezomib combined with dexamethasone and thalidomide can effectively reduce the inflammatory response, M protein and myeloma cells in patients with MM, significantly improve the immune function and renal function in patients, which has certain clinical application value.
